1 citations,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
59 citations,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
489 citations,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
76 citations,
October 2000 in “Journal of the American Academy of Dermatology” Follicular mucinosis can be an early sign of aggressive mycosis fungoides.
40 citations,
October 2012 in “Journal of the American Academy of Dermatology” CLASI is a valid tool for assessing skin activity and damage in lupus patients.
32 citations,
August 1982 in “Journal of the American Academy of Dermatology” GLPLS and LPP are variants of lichen planus.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
2 citations,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.